Key clinical point: For patients with immune thrombocytopenia (ITP), platelet glycoprotein genotypes may predict responses to specific therapies.
Major finding: All patients who had durable responses to second-line splenectomy exhibited the GPIa A1648G genotype, compared with 44% of splenectomy nonresponders (odds ratio, 33.0; P = .005).
Study details: An observational study involving 81 patients with ITP.
Disclosures: The investigators reported no study funding or conflicts of interest.
Zotova I et al. EHA Congress, Abstract S848